Eli Lilly to Pull Cancer Drug From Market After Failed Study

Eli Lilly & Co. said Thursday it plans to withdraw its cancer drug Lartruvo from the market after a study showed that it failed to prolong overall survival in a clinical trial.

The company will establish an access program to allow some patients with soft-tissue sarcoma—a cancer that develops in connective tissue including muscle—to continue taking the drug with limited interruption after it’s withdrawn from the market. Lilly didn’t provide a specific timeline and said it’s working with health regulators on its plans.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Federal opioid pill bust reveals doctors trading pills for sex, dentists pulling good teethThey're all accused of illegally prescribing pain meds, but charges against these medical professionals are the most shocking from this week's sweep. In India they murder and get away Bring the hammer down on those corporately 'licensed' dope dealers They need On the Count a Travelers Guide To Prison by Anonymous available on Amazon
Source: USATODAY - 🏆 100. / 63 Read more »